{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:57:33Z","timestamp":1794272253228,"version":"4.9.0"},"reference-count":276,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nanotechnology has revolutionized cancer therapy by introducing advanced drug delivery systems that enhance therapeutic efficacy while reducing adverse effects. By leveraging various nanoparticle platforms\u2014including liposomes, polymeric nanoparticles, and inorganic nanoparticles\u2014researchers have improved drug solubility, stability, and bioavailability. Additionally, new nanodevices are being engineered to respond to specific physiological conditions like temperature and pH variations, enabling controlled drug release and optimizing therapeutic outcomes. Beyond drug delivery, nanotechnology plays a crucial role in the theranostic field due to the functionalization of specific materials that combine tumor detection and targeted treatment features. This review analyzes the clinical impact of nanotechnology, spanning from early-phase trials to pivotal phase 3 studies that have obtained regulatory approval, while also offering a critical perspective on the preclinical domain and its translational potential for future human applications. Despite significant progress, greater attention must be placed on key challenges, such as biocompatibility barriers and the lack of regulatory standardization, to ensure the successful translation of nanomedicine into routine clinical practice.<\/jats:p>","DOI":"10.1186\/s40164-025-00656-1","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T09:08:27Z","timestamp":1747645707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Developments in nanotechnology approaches for the treatment of solid tumors"],"prefix":"10.1186","volume":"14","author":[{"given":"Jacopo","family":"Venturini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Baysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"3","key":"656_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"656_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"656_CR3","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","volume":"16","author":"BH Herzog","year":"2021","unstructured":"Herzog BH, Devarakonda S, Govindan R. Overcoming chemotherapy resistance in SCLC. J Thorac Oncol. 2021;16(12):2002\u201315.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"656_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9\u201316.","journal-title":"Br J Cancer"},{"issue":"1","key":"656_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/molecules25010112","volume":"25","author":"S Bayda","year":"2019","unstructured":"Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine. Molecules. 2019;25(1):112.","journal-title":"Molecules"},{"issue":"Pt 2","key":"656_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.semcancer.2021.08.003","volume":"86","author":"X Su","year":"2022","unstructured":"Su X, Zhang X, Liu W, Yang X, An N, Yang F, Sun J, Xing Y, Shang H. Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. Semin Cancer Biol. 2022;86(Pt 2):929\u201342.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"656_CR7","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1039\/D3MH00265A","volume":"10","author":"LRH Gerken","year":"2023","unstructured":"Gerken LRH, Gerdes ME, Pruschy M, Herrmann IK. Prospects of nanoparticle-based radioenhancement for radiotherapy. Mater Horiz. 2023;10(10):4059\u201382.","journal-title":"Mater Horiz"},{"issue":"9","key":"656_CR8","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1021\/acs.molpharmaceut.8b00037","volume":"15","author":"ZR Lu","year":"2018","unstructured":"Lu ZR, Qiao P. Drug delivery in cancer therapy, quo vadis? Mol Pharm. 2018;15(9):3603\u201316.","journal-title":"Mol Pharm"},{"issue":"2","key":"656_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/17425247.2016.1211637","volume":"14","author":"RR Castillo","year":"2017","unstructured":"Castillo RR, Colilla M, Vallet-Regi M. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv. 2017;14(2):229\u201343.","journal-title":"Expert Opin Drug Deliv"},{"key":"656_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jconrel.2020.09.017","volume":"328","author":"M Saadat","year":"2020","unstructured":"Saadat M, Manshadi MKD, Mohammadi M, Zare MJ, Zarei M, Kamali R, Sanati-Nezhad A. Magnetic particle targeting for diagnosis and therapy of lung cancers. J Control Release. 2020;328:776\u201391.","journal-title":"J Control Release"},{"key":"656_CR11","doi-asserted-by":"publisher","first-page":"8483","DOI":"10.2147\/IJN.S148359","volume":"12","author":"J Zhang","year":"2017","unstructured":"Zhang J, Tang H, Liu Z, Chen B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy. Int J Nanomedicine. 2017;12:8483\u201393.","journal-title":"Int J Nanomedicine"},{"key":"656_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.techfore.2014.09.007","volume":"94","author":"M Coccia","year":"2015","unstructured":"Coccia M, Wang L. Path-breaking directions of nanotechnology-based chemotherapy and molecular cancer therapy. Technol Forecast Soc Chang. 2015;94:155\u201369.","journal-title":"Technol Forecast Soc Chang"},{"issue":"1","key":"656_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/1871520617666170419143459","volume":"18","author":"N Zhao","year":"2018","unstructured":"Zhao N, Qin Y, Liu H, Cheng Z. Tumor-targeting peptides: ligands for molecular imaging and therapy. Anticancer Agents Med Chem. 2018;18(1):74\u201386.","journal-title":"Anticancer Agents Med Chem"},{"issue":"5","key":"656_CR14","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.7150\/thno.69628","volume":"12","author":"L Tang","year":"2022","unstructured":"Tang L, Li J, Pan T, Yin Y, Mei Y, Xiao Q, Wang R, Yan Z, Wang W. Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives. Theranostics. 2022;12(5):2290\u2013321.","journal-title":"Theranostics"},{"key":"656_CR15","first-page":"63","volume-title":"There\u2019s plenty of room at the bottom, Feynman and computation","author":"R Feynman","year":"2018","unstructured":"Feynman R. There\u2019s plenty of room at the bottom, Feynman and computation. Boca Raton: CRC Press; 2018. p. 63\u201376."},{"issue":"5","key":"656_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1089\/blr.2011.9814","volume":"30","author":"D Guidance","year":"2011","unstructured":"Guidance D. Guidance for industry considering whether an FDA-regulated product involves the application of nanotechnology. Biotechnol Law Rep. 2011;30(5):613\u20136.","journal-title":"Biotechnol Law Rep"},{"issue":"2","key":"656_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00253-012-3969-4","volume":"94","author":"M Rai","year":"2012","unstructured":"Rai M, Ingle A. Role of nanotechnology in agriculture with special reference to management of insect pests. Appl Microbiol Biotechnol. 2012;94(2):287\u201393.","journal-title":"Appl Microbiol Biotechnol"},{"key":"656_CR18","first-page":"1","volume":"1","author":"R Frietas Jr","year":"1999","unstructured":"Frietas R Jr. Nanomedicine: basic capabilities. Austin Landes Biosci. 1999;1:1.","journal-title":"Austin Landes Biosci"},{"issue":"7","key":"656_CR19","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","volume":"12","author":"X Shan","year":"2022","unstructured":"Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12(7):3028\u201348.","journal-title":"Acta Pharm Sin B"},{"issue":"13","key":"656_CR20","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.1039\/D2RA07863E","volume":"13","author":"MJ Nirmala","year":"2023","unstructured":"Nirmala MJ, Kizhuveetil U, Johnson A. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead. RSC Adv. 2023;13(13):8606\u201329.","journal-title":"RSC Adv"},{"key":"656_CR21","doi-asserted-by":"crossref","unstructured":"Barenholz, Y.C., Doxil\u00ae\u2014The first FDA-approved nano-drug: From an idea to a product, in Handbook of harnessing biomaterials in nanomedicine. 2021, Jenny Stanford Publishing. p. 463\u2013528.","DOI":"10.1201\/9781003125259-16"},{"issue":"5","key":"656_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10637-006-6214-0","volume":"24","author":"VJ Lee","year":"2006","unstructured":"Lee VJ, Divyesh M, Latha R. Abraxane\u00ae induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest New Drugs. 2006;24(5):455\u20136.","journal-title":"Invest New Drugs"},{"issue":"7291","key":"656_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067\u201370.","journal-title":"Nature"},{"issue":"27","key":"656_CR24","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1073\/pnas.1106634108","volume":"108","author":"CM Hu","year":"2011","unstructured":"Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"656_CR25","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684\u201392.","journal-title":"J Clin Oncol"},{"issue":"6604","key":"656_CR26","doi-asserted-by":"publisher","first-page":"eabm5551","DOI":"10.1126\/science.abm5551","volume":"377","author":"N Boehnke","year":"2022","unstructured":"Boehnke N, Straehla JP, Safford HC, Kocak M, Rees MG, Ronan M, Rosenberg D, Adelmann CH, Chivukula RR, Nabar N, et al. Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery. Science. 2022;377(6604):eabm5551.","journal-title":"Science"},{"issue":"5","key":"656_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"issue":"10427","key":"656_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344.","journal-title":"Lancet"},{"issue":"3","key":"656_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc1566","volume":"5","author":"M Ferrari","year":"2005","unstructured":"Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161\u201371.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"656_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"656_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/jpm11030229","volume":"11","author":"H Maeda","year":"2021","unstructured":"Maeda H. The 35th anniversary of the discovery of EPR Effect: a new wave of nanomedicines for tumor-targeted drug delivery-personal remarks and future prospects. J Pers Med. 2021;11(3):229.","journal-title":"J Pers Med"},{"issue":"12 Pt 1","key":"656_CR32","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387\u201392.","journal-title":"Cancer Res"},{"issue":"12","key":"656_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751\u201360.","journal-title":"Nat Nanotechnol"},{"issue":"6","key":"656_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/jpm11060571","volume":"11","author":"MA Subhan","year":"2021","unstructured":"Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP. Recent advances in tumor targeting via EPR effect for cancer treatment. J Pers Med. 2021;11(6):571.","journal-title":"J Pers Med"},{"issue":"17","key":"656_CR35","doi-asserted-by":"publisher","first-page":"11476","DOI":"10.1021\/acs.chemrev.7b00194","volume":"117","author":"C Kinnear","year":"2017","unstructured":"Kinnear C, Moore TL, Rodriguez-Lorenzo L, Rothen-Rutishauser B, Petri-Fink A. Form follows function: nanoparticle shape and its implications for nanomedicine. Chem Rev. 2017;117(17):11476\u2013521.","journal-title":"Chem Rev"},{"key":"656_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","volume":"201","author":"IA Khawar","year":"2015","unstructured":"Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release. 2015;201:78\u201389.","journal-title":"J Control Release"},{"key":"656_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","volume":"91","author":"H Maeda","year":"2015","unstructured":"Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3\u20136.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"656_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40169-018-0185-6","volume":"7","author":"H Maeda","year":"2018","unstructured":"Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med. 2018;7(1):11.","journal-title":"Clin Transl Med"},{"issue":"1","key":"656_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1519","volume":"11","author":"YR Zhang","year":"2019","unstructured":"Zhang YR, Lin R, Li HJ, He WL, Du JZ, Wang J. Strategies to improve tumor penetration of nanomedicines through nanoparticle design. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(1): e1519.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"656_CR40","first-page":"2891","volume":"7","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Wang L, Yan M, Ma Y, Zang G, She Z, Deng Y. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomed. 2012;7:2891\u2013900.","journal-title":"Int J Nanomed"},{"issue":"13","key":"656_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/polym14132601","volume":"14","author":"V Ejigah","year":"2022","unstructured":"Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. polymers. 2022;14(13):4.","journal-title":"polymers"},{"issue":"1","key":"656_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12951-023-01826-1","volume":"21","author":"P Shi","year":"2023","unstructured":"Shi P, Cheng Z, Zhao K, Chen Y, Zhang A, Gan W, Zhang Y. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J Nanobiotechnol. 2023;21(1):103.","journal-title":"J Nanobiotechnol"},{"key":"656_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.110298","volume":"106","author":"Z He","year":"2020","unstructured":"He Z, Zhang Y, Feng N. Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: A review. Mater Sci Eng C Mater Biol Appl. 2020;106: 110298.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"1","key":"656_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adhm.201700607","volume":"7","author":"AJ Sivaram","year":"2018","unstructured":"Sivaram AJ, Wardiana A, Howard CB, Mahler SM, Thurecht KJ. Recent advances in the generation of antibody-nanomaterial conjugates. Adv Healthc Mater. 2018;7(1):1.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"656_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1039\/C6SC02403C","volume":"8","author":"DA Richards","year":"2017","unstructured":"Richards DA, Maruani A, Chudasama V. Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem Sci. 2017;8(1):63\u201377.","journal-title":"Chem Sci"},{"issue":"6","key":"656_CR46","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1039\/D0BM01904F","volume":"9","author":"R Chen","year":"2021","unstructured":"Chen R, Huang Y, Wang L, Zhou J, Tan Y, Peng C, Yang P, Peng W, Li J, Gu Q, et al. Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. Biomater Sci. 2021;9(6):2279\u201394.","journal-title":"Biomater Sci"},{"issue":"12","key":"656_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano9121793","volume":"9","author":"E Niza","year":"2019","unstructured":"Niza E, Noblejas-Lopez MDM, Bravo I, Nieto-Jimenez C, Castro-Osma JA, Canales-Vazquez J, Lara-Sanchez A, Galan Moya EM, Burgos M, Ocana A, et al. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastasic breast cancer. Nanomaterials. 2019;9(12):1.","journal-title":"Nanomaterials"},{"issue":"9","key":"656_CR48","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.1021\/nn101000e","volume":"4","author":"HS Cho","year":"2010","unstructured":"Cho HS, Dong Z, Pauletti GM, Zhang J, Xu H, Gu H, Wang L, Ewing RC, Huth C, Wang F, et al. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano. 2010;4(9):5398\u2013404.","journal-title":"ACS Nano"},{"issue":"19","key":"656_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13194891","volume":"13","author":"JF Xiao","year":"2021","unstructured":"Xiao JF, Caliri AW, Duex JE, Theodorescu D. Targetable pathways in advanced bladder cancer: FGFR signaling. Cancers. 2021;13(19):1.","journal-title":"Cancers"},{"issue":"6","key":"656_CR50","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1021\/mp200402e","volume":"8","author":"D Liu","year":"2011","unstructured":"Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm. 2011;8(6):2291\u2013301.","journal-title":"Mol Pharm"},{"key":"656_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.addr.2020.02.004","volume":"163\u2013164","author":"ALB Seynhaeve","year":"2020","unstructured":"Seynhaeve ALB, Amin M, Haemmerich D, van Rhoon GC, Ten Hagen TLM. Hyperthermia and smart drug delivery systems for solid tumor therapy. Adv Drug Deliv Rev. 2020;163\u2013164:125\u201344.","journal-title":"Adv Drug Deliv Rev"},{"key":"656_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.addr.2016.05.021","volume":"109","author":"S Stapleton","year":"2017","unstructured":"Stapleton S, Jaffray D, Milosevic M. Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery. Adv Drug Deliv Rev. 2017;109:119\u201330.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"656_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1527","volume":"11","author":"Y Qiao","year":"2019","unstructured":"Qiao Y, Wan J, Zhou L, Ma W, Yang Y, Luo W, Yu Z, Wang H. Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(1): e1527.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"11","key":"656_CR54","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.addr.2012.01.002","volume":"64","author":"R de la Rica","year":"2012","unstructured":"de la Rica R, Aili D, Stevens MM. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev. 2012;64(11):967\u201378.","journal-title":"Adv Drug Deliv Rev"},{"key":"656_CR55","doi-asserted-by":"publisher","first-page":"9447","DOI":"10.2147\/IJN.S274289","volume":"15","author":"X Wang","year":"2020","unstructured":"Wang X, Qiu Y, Wang M, Zhang C, Zhang T, Zhou H, Zhao W, Zhao W, Xia G, Shao R. Endocytosis and organelle targeting of nanomedicines in cancer therapy. Int J Nanomedicine. 2020;15:9447\u201367.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"656_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"656_CR57","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.2174\/0929867326666190129142604","volume":"27","author":"M Fernandes","year":"2020","unstructured":"Fernandes M, Lopes I, Teixeira J, Botelho C, Gomes AC. Exosome-like nanoparticles: a new type of nanocarrier. Curr Med Chem. 2020;27(23):3888\u2013905.","journal-title":"Curr Med Chem"},{"issue":"27","key":"656_CR58","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.2174\/1381612826666200622133407","volume":"26","author":"B Layek","year":"2020","unstructured":"Layek B, Gidwani B, Tiwari S, Joshi V, Jain V, Vyas A. Recent advances in lipid-based nanodrug delivery systems in cancer therapy. Curr Pharm Des. 2020;26(27):3218\u201333.","journal-title":"Curr Pharm Des"},{"key":"656_CR59","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/IJN.S68861","volume":"10","author":"G Bozzuto","year":"2015","unstructured":"Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975\u201399.","journal-title":"Int J Nanomed"},{"issue":"1","key":"656_CR60","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/21691401.2023.2247036","volume":"51","author":"S Pande","year":"2023","unstructured":"Pande S. Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes. Artif Cells Nanomed Biotechnol. 2023;51(1):428\u201340.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"3","key":"656_CR61","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440\u20139.","journal-title":"Ann Oncol"},{"issue":"7","key":"656_CR62","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","volume":"16","author":"U Jacobi","year":"2005","unstructured":"Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, Sterry W, Lademann J. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210\u20131.","journal-title":"Ann Oncol"},{"issue":"3","key":"656_CR63","doi-asserted-by":"publisher","first-page":"pbae017","DOI":"10.1093\/pcmedi\/pbae017","volume":"7","author":"EM Jacob","year":"2024","unstructured":"Jacob EM, Huang J, Chen M. Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology. Precis Clin Med. 2024;7(3):pbae017.","journal-title":"Precis Clin Med"},{"issue":"3","key":"656_CR64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/apb.2015.043","volume":"5","author":"N Naseri","year":"2015","unstructured":"Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305\u201313.","journal-title":"Adv Pharm Bull"},{"key":"656_CR65","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ijpharm.2019.04.006","volume":"563","author":"I Vhora","year":"2019","unstructured":"Vhora I, Lalani R, Bhatt P, Patil S, Misra A. Lipid-nucleic acid nanoparticles of novel ionizable lipids for systemic BMP-9 gene delivery to bone-marrow mesenchymal stem cells for osteoinduction. Int J Pharm. 2019;563:324\u201336.","journal-title":"Int J Pharm"},{"issue":"2","key":"656_CR66","doi-asserted-by":"publisher","first-page":"150","DOI":"10.34172\/apb.2020.021","volume":"10","author":"I Chauhan","year":"2020","unstructured":"Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery. Adv Pharm Bull. 2020;10(2):150\u201365.","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"656_CR67","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"B Wang","year":"2024","unstructured":"Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, Wang K, Xu J, Cheng Y, Gao X. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9(1):200.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"656_CR68","doi-asserted-by":"publisher","first-page":"L187","DOI":"10.1152\/ajplung.00152.2002","volume":"284","author":"TA John","year":"2003","unstructured":"John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 2003;284(1):L187\u201396.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"8","key":"656_CR69","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"656_CR70","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CMAR.S150960","volume":"10","author":"RL Mahtani","year":"2018","unstructured":"Mahtani RL, Parisi M, Gluck S, Ni Q, Park S, Pelletier C, Faria C, Braiteh F. Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis. Cancer Manag Res. 2018;10:249\u201356.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"656_CR71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/biomedicines11072000","volume":"11","author":"MS Hassan","year":"2023","unstructured":"Hassan MS, Awasthi N, Ponna S, von Holzen U. Nab-paclitaxel in the treatment of gastrointestinal cancers-improvements in clinical efficacy and safety. Biomedicines. 2023;11(7):249.","journal-title":"Biomedicines"},{"issue":"2","key":"656_CR72","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505\u201322.","journal-title":"J Control Release"},{"issue":"2 Suppl 1","key":"656_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0090-4295(02)02396-8","volume":"61","author":"O Sartor","year":"2003","unstructured":"Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology. 2003;61(2 Suppl 1):25\u201331.","journal-title":"Urology"},{"key":"656_CR74","doi-asserted-by":"publisher","first-page":"118814","DOI":"10.1016\/j.ijpharm.2019.118814","volume":"573","author":"AP Dias","year":"2020","unstructured":"Dias AP, da Silva Santos S, da Silva JV, Parise-Filho R, Igne Ferreira E, Seoud OE, Giarolla J. Dendrimers in the context of nanomedicine. Int J Pharm. 2020;573:118814.","journal-title":"Int J Pharm"},{"issue":"14","key":"656_CR75","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1021\/acs.chemrev.8b00199","volume":"118","author":"H Cabral","year":"2018","unstructured":"Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev. 2018;118(14):6844\u201392.","journal-title":"Chem Rev"},{"issue":"1\u20132","key":"656_CR76","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijpharm.2018.01.034","volume":"539","author":"A Pugazhendhi","year":"2018","unstructured":"Pugazhendhi A, Edison T, Karuppusamy I, Kathirvel B. Inorganic nanoparticles: a potential cancer therapy for human welfare. Int J Pharm. 2018;539(1\u20132):104\u201311.","journal-title":"Int J Pharm"},{"issue":"1","key":"656_CR77","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12943-023-01798-8","volume":"22","author":"P Kesharwani","year":"2023","unstructured":"Kesharwani P, Ma R, Sang L, Fatima M, Sheikh A, Abourehab MAS, Gupta N, Chen ZS, Zhou Y. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023;22(1):98.","journal-title":"Mol Cancer"},{"issue":"12","key":"656_CR78","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/tcr.202000087","volume":"20","author":"J Fan","year":"2020","unstructured":"Fan J, Cheng Y, Sun M. Functionalized gold nanoparticles: synthesis, properties and biomedical applications. Chem Rec. 2020;20(12):1474\u2013504.","journal-title":"Chem Rec"},{"issue":"9","key":"656_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules22091445","volume":"22","author":"FY Kong","year":"2017","unstructured":"Kong FY, Zhang JW, Li RF, Wang ZX, Wang WJ, Wang W. Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications. Molecules. 2017;22(9):4.","journal-title":"Molecules"},{"issue":"4","key":"656_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ma16041453","volume":"16","author":"H Guo","year":"2023","unstructured":"Guo H, Hu Q, Zhang C, Liu H, Wu R, Pan S. Strong plasmon-mie resonance in Si@Pd core-omega shell nanocavity. Materials. 2023;16(4):1.","journal-title":"Materials"},{"issue":"15","key":"656_CR81","doi-asserted-by":"publisher","first-page":"8459","DOI":"10.1039\/C4NR00464G","volume":"6","author":"CB Collins","year":"2014","unstructured":"Collins CB, McCoy RS, Ackerson BJ, Collins GJ, Ackerson CJ. Radiofrequency heating pathways for gold nanoparticles. Nanoscale. 2014;6(15):8459\u201372.","journal-title":"Nanoscale"},{"key":"656_CR82","doi-asserted-by":"crossref","unstructured":"Maharana PK, Srivastava t, Jha R. Surface plasmon resonance imaging biosensor based on graphene multilayer. in International Conference on Fibre Optics and Photonics. 2012. Chennai: Optica Publishing Group.","DOI":"10.1364\/PHOTONICS.2012.TPo.21"},{"issue":"1","key":"656_CR83","first-page":"3623963","volume":"2022","author":"L Xu","year":"2022","unstructured":"Xu L, Wang H, Si W. Surface plasmon resonance sterilization 3d imaging technology considering the engineering hue algorithm. Mob Inf Syst. 2022;2022(1):3623963.","journal-title":"Mob Inf Syst"},{"key":"656_CR84","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cej.2018.11.156","volume":"359","author":"F Farjadian","year":"2019","unstructured":"Farjadian F, Roointan A, Mohammadi-Samani S, Hosseini M. Mesoporous silica nanoparticles: synthesis, pharmaceutical applications, biodistribution, and biosafety assessment. Chem Eng J. 2019;359:684\u2013705.","journal-title":"Chem Eng J"},{"issue":"13","key":"656_CR85","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1039\/D1CS00659B","volume":"51","author":"M Vallet-Regi","year":"2022","unstructured":"Vallet-Regi M, Schuth F, Lozano D, Colilla M, Manzano M. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev. 2022;51(13):5365\u2013451.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"656_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/pharmaceutics13010071","volume":"13","author":"T Moodley","year":"2021","unstructured":"Moodley T, Singh M. Current stimuli-responsive mesoporous silica nanoparticles for cancer therapy. Pharmaceutics. 2021;13(1):71.","journal-title":"Pharmaceutics"},{"key":"656_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.crgsc.2020.100042","volume":"4","author":"AV Samrot","year":"2021","unstructured":"Samrot AV, Sahithya CS, Selvarani J, Purayil SK, Ponnaiah P. A review on synthesis, characterization and potential biological applications of superparamagnetic iron oxide nanoparticles. CurR Res Green Sustain Chem. 2021;4: 100042.","journal-title":"CurR Res Green Sustain Chem"},{"issue":"9","key":"656_CR88","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3390\/molecules27092763","volume":"27","author":"ME Nikolaeva","year":"2022","unstructured":"Nikolaeva ME, Nechaev AV, Shmendel EV, Akasov RA, Maslov MA, Mironov AF. New cysteine-containing PEG-Glycerolipid Increases the bloodstream circulation time of upconverting nanoparticles. Molecules. 2022;27(9):2763.","journal-title":"Molecules"},{"issue":"11","key":"656_CR89","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nnano.2016.164","volume":"11","author":"SE Kim","year":"2016","unstructured":"Kim SE, Zhang L, Ma K, Riegman M, Chen F, Ingold I, Conrad M, Turker MZ, Gao M, Jiang X, et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol. 2016;11(11):977\u201385.","journal-title":"Nat Nanotechnol"},{"issue":"55","key":"656_CR90","doi-asserted-by":"publisher","first-page":"93800","DOI":"10.18632\/oncotarget.21191","volume":"8","author":"Y Pang","year":"2017","unstructured":"Pang Y, Mai Z, Wang B, Wang L, Wu L, Wang X, Chen T. Artesunate-modified nano-graphene oxide for chemo-photothermal cancer therapy. Oncotarget. 2017;8(55):93800\u201312.","journal-title":"Oncotarget"},{"issue":"6","key":"656_CR91","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/biomedicines10061374","volume":"10","author":"MS Kang","year":"2022","unstructured":"Kang MS, Lee H, Jeong SJ, Eom TJ, Kim J, Han DW. State of the art in carbon nanomaterials for photoacoustic imaging. Biomedicines. 2022;10(6):55.","journal-title":"Biomedicines"},{"issue":"1","key":"656_CR92","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","volume":"5","author":"J Dai","year":"2020","unstructured":"Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5(1):145.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"656_CR93","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","volume":"23","author":"EI Buzas","year":"2023","unstructured":"Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23(4):236\u201350.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"656_CR94","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1200\/JCO.1997.15.2.653","volume":"15","author":"DW Northfelt","year":"1997","unstructured":"Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi\u2019s sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997;15(2):653\u20139.","journal-title":"J Clin Oncol"},{"key":"656_CR95","doi-asserted-by":"crossref","unstructured":"Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ, 1998. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol, 16(2): 683\u201391.","DOI":"10.1200\/JCO.1998.16.2.683"},{"key":"656_CR96","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/00016347609156447","volume":"54","author":"E Weiner","year":"1976","unstructured":"Weiner E, Victor A, Johansson ED. New delivery systems for D-norgestrel. Acta Obstet Gynecol Scand Suppl. 1976;54:35\u201343.","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"issue":"1","key":"656_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","volume":"95","author":"AN Gordon","year":"2004","unstructured":"Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1\u20138.","journal-title":"Gynecol Oncol"},{"issue":"25","key":"656_CR98","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","volume":"25","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892\u2013901.","journal-title":"J Clin Oncol"},{"key":"656_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0960-9776(01)80001-1","volume":"10","author":"C Swenson","year":"2001","unstructured":"Swenson C, Perkins W, Roberts P, Janoff A. Liposome technology and the development of Myocet\u2122(liposomal doxorubicin citrate). The Breast. 2001;10:1\u20137.","journal-title":"The Breast"},{"issue":"31","key":"656_CR100","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794\u2013803.","journal-title":"J Clin Oncol"},{"issue":"25","key":"656_CR101","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1200\/JCO.2005.11.013","volume":"23","author":"NK Ibrahim","year":"2005","unstructured":"Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23(25):6019\u201326.","journal-title":"J Clin Oncol"},{"issue":"17","key":"656_CR102","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055\u201362.","journal-title":"J Clin Oncol"},{"issue":"18","key":"656_CR103","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"8","key":"656_CR104","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","volume":"73","author":"U Prabhakar","year":"2013","unstructured":"Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412\u20137.","journal-title":"Cancer Res"},{"issue":"10018","key":"656_CR105","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"issue":"10409","key":"656_CR106","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, Dean A, Kiss I, Lee WJ, Goetze TO, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381.","journal-title":"Lancet"},{"issue":"10","key":"656_CR107","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","volume":"17","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110\u20136.","journal-title":"J Clin Oncol"},{"issue":"11","key":"656_CR108","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"656_CR109","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O\u2019Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13(6):903\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"656_CR110","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29\u201335.","journal-title":"Ann Oncol"},{"issue":"6","key":"656_CR111","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178\u201384.","journal-title":"J Clin Oncol"},{"issue":"22","key":"656_CR112","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the aprepitant protocol 052 study group. J Clin Oncol. 2003;21(22):4112\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"656_CR113","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","volume":"4","author":"L Gianni","year":"2018","unstructured":"Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, et al. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018;4(3):302\u20138.","journal-title":"JAMA Oncol"},{"issue":"25","key":"656_CR114","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1200\/JCO.18.01842","volume":"37","author":"M Untch","year":"2019","unstructured":"Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kummel S, Warm M, et al. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto. J Clin Oncol. 2019;37(25):2226\u201334.","journal-title":"J Clin Oncol"},{"issue":"5","key":"656_CR115","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","volume":"120","author":"Y Fujiwara","year":"2019","unstructured":"Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer. 2019;120(5):475\u201380.","journal-title":"Br J Cancer"},{"key":"656_CR116","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejca.2017.02.011","volume":"76","author":"C Twelves","year":"2017","unstructured":"Twelves C, Cortes J, O\u2019Shaughnessy J, Awada A, Perez EA, Im SA, Gomez-Pardo P, Schwartzberg LS, Dieras V, Yardley DA, et al. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician\u2019s choice: Results from the randomised phase III BEACON trial. Eur J Cancer. 2017;76:205\u201315.","journal-title":"Eur J Cancer"},{"issue":"1","key":"656_CR117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1078-0432.CCR-16-2433","volume":"24","author":"WY Tak","year":"2018","unstructured":"Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, et al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res. 2018;24(1):73\u201383.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"656_CR118","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824\u201330.","journal-title":"JAMA Oncol"},{"issue":"11","key":"656_CR119","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","volume":"30","author":"SK Maithel","year":"2023","unstructured":"Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30(11):6558\u201366.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"656_CR120","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12032-021-01479-w","volume":"38","author":"P Oppelt","year":"2021","unstructured":"Oppelt P, Ley J, Daly M, Rich J, Paniello R, Jackson RS, Pipkorn P, Liu J, Gay H, Palka K, et al. nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. Med Oncol. 2021;38(4):35.","journal-title":"Med Oncol"},{"issue":"10","key":"656_CR121","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","volume":"4","author":"KA Autio","year":"2018","unstructured":"Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 2018;4(10):1344\u201351.","journal-title":"JAMA Oncol"},{"issue":"5","key":"656_CR122","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s10637-011-9757-7","volume":"30","author":"JL Lee","year":"2012","unstructured":"Lee JL, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs. 2012;30(5):1984\u201390.","journal-title":"Invest New Drugs"},{"issue":"7","key":"656_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154009","volume":"11","author":"M Ignatiadis","year":"2016","unstructured":"Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D\u2019Hondt V, De Azambuja E, Gombos A, Lebrun F, Dal Lago L, et al. Feasibility study of endotag-1, a tumor endothelial targeting agent, in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer. PLoS ONE. 2016;11(7): e0154009.","journal-title":"PLoS ONE"},{"key":"656_CR124","volume":"75","author":"P Xing","year":"2024","unstructured":"Xing P, Wang S, Bi M, Liu Y, Zeng J, Wang X, Xiao K, Li W, Guo J, Wang P, et al. Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer. EClin Med. 2024;75: 102791.","journal-title":"EClin Med"},{"key":"656_CR125","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.nano.2019.02.021","volume":"18","author":"HK Sanoff","year":"2019","unstructured":"Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, O\u2019Neil BH, Subramaniam S, McRee AJ, Carlson C, et al. Phase I\/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine. 2019;18:189\u201395.","journal-title":"Nanomedicine"},{"issue":"1","key":"656_CR126","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-17-1114","volume":"24","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, et al. Phase Ib\/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors. Clin Cancer Res. 2018;24(1):43\u201351.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"656_CR127","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/JU.0000000000004222","volume":"212","author":"SE Canfield","year":"2024","unstructured":"Canfield SE, George AK, Jue JS, Lewis SC, Davenport MS, Tammisetti VS, Maruf M, Borregalaes LD, Kadria-Vili Y, Schwartz JA, et al. A multi-institutional study of magnetic resonance\/ultrasound fusion-guided nanoparticle-directed focal therapy for prostate ablation. J Urol. 2024;212(6):862\u201372.","journal-title":"J Urol"},{"issue":"3","key":"656_CR128","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.surg.2016.04.017","volume":"160","author":"W Yu","year":"2016","unstructured":"Yu W, Cao X, Xu G, Song Y, Li G, Zheng H, Zhang N. Potential role for carbon nanoparticles to guide central neck dissection in patients with papillary thyroid cancer. Surgery. 2016;160(3):755\u201361.","journal-title":"Surgery"},{"issue":"4","key":"656_CR129","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1071008","volume":"5","author":"B Besse","year":"2016","unstructured":"Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4): e1071008.","journal-title":"Oncoimmunology"},{"issue":"2","key":"656_CR130","doi-asserted-by":"publisher","first-page":"B209","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-B209","volume":"7","author":"J Sabari","year":"2019","unstructured":"Sabari J, Ramirez KA, Schwarzenberger P, Ricciardi T, Macri M, Ryan A, Venhaus R. Abstract B209: Phase 1\/2 study of mRNA vaccine therapy + durvalumab (durva) \u00b1 tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Cancer Immunol Res. 2019;7(2):B209\u2013B209.","journal-title":"Cancer Immunol Res"},{"issue":"7963","key":"656_CR131","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"10","key":"656_CR132","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","volume":"187","author":"HR Mendez-Gomez","year":"2024","unstructured":"Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, Xie C, Weidert F, Zhao C, Moor R, et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell. 2024;187(10):2521\u2013253521.","journal-title":"Cell"},{"issue":"10","key":"656_CR133","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386\u201396.","journal-title":"Lancet Oncol"},{"issue":"45","key":"656_CR134","doi-asserted-by":"publisher","first-page":"13194","DOI":"10.1021\/acs.langmuir.1c01370","volume":"37","author":"K De","year":"2021","unstructured":"De K. Decapeptide modified doxorubicin loaded solid lipid nanoparticles as targeted drug delivery system against prostate cancer. Langmuir. 2021;37(45):13194\u2013207.","journal-title":"Langmuir"},{"key":"656_CR135","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejps.2017.12.011","volume":"114","author":"E Moghimipour","year":"2018","unstructured":"Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, Angali KA, Dorkoosh FA, Handali S. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil. Eur J Pharm Sci. 2018;114:166\u201374.","journal-title":"Eur J Pharm Sci"},{"key":"656_CR136","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.biopha.2018.09.128","volume":"108","author":"S Handali","year":"2018","unstructured":"Handali S, Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, Angali KA, Saremy S, Dorkoosh FA. A novel 5-Fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes. Biomed Pharmacother. 2018;108:1259\u201373.","journal-title":"Biomed Pharmacother"},{"issue":"33","key":"656_CR137","doi-asserted-by":"publisher","first-page":"8382","DOI":"10.1016\/j.biomaterials.2013.07.070","volume":"34","author":"J Li","year":"2013","unstructured":"Li J, Zheng L, Cai H, Sun W, Shen M, Zhang G, Shi X. Polyethyleneimine-mediated synthesis of folic acid-targeted iron oxide nanoparticles for in vivo tumor MR imaging. Biomaterials. 2013;34(33):8382\u201392.","journal-title":"Biomaterials"},{"issue":"2","key":"656_CR138","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/nnm.13.20","volume":"9","author":"J Gao","year":"2014","unstructured":"Gao J, Xia Y, Chen H, Yu Y, Song J, Li W, Qian W, Wang H, Dai J, Guo Y. Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond). 2014;9(2):279\u201393.","journal-title":"Nanomedicine (Lond)"},{"issue":"40","key":"656_CR139","doi-asserted-by":"publisher","first-page":"12486","DOI":"10.1073\/pnas.1517048112","volume":"112","author":"AJ Clark","year":"2015","unstructured":"Clark AJ, Davis ME. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc Natl Acad Sci USA. 2015;112(40):12486\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"656_CR140","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2217\/nnm-2016-0147","volume":"11","author":"M Sambade","year":"2016","unstructured":"Sambade M, Deal A, Schorzman A, Luft JC, Bowerman C, Chu K, Karginova O, Swearingen AV, Zamboni W, DeSimone J, et al. Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT((R)) nanoparticle formulation against non-small-cell lung cancer brain metastases. Nanomedicine. 2016;11(15):1947\u201355.","journal-title":"Nanomedicine"},{"key":"656_CR141","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.actbio.2019.09.003","volume":"99","author":"X Chen","year":"2019","unstructured":"Chen X, Yu Q, Liu Y, Sheng Q, Shi K, Wang Y, Li M, Zhang Z, He Q. Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes. Acta Biomater. 2019;99:339\u201349.","journal-title":"Acta Biomater"},{"issue":"6","key":"656_CR142","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41565-023-01374-7","volume":"18","author":"Z Luo","year":"2023","unstructured":"Luo Z, Lu Y, Shi Y, Jiang M, Shan X, Li X, Zhang J, Qin B, Liu X, Guo X, et al. Neutrophil hitchhiking for drug delivery to the bone marrow. Nat Nanotechnol. 2023;18(6):647\u201356.","journal-title":"Nat Nanotechnol"},{"issue":"23","key":"656_CR143","doi-asserted-by":"publisher","first-page":"21677","DOI":"10.1021\/am506849p","volume":"6","author":"S Goel","year":"2014","unstructured":"Goel S, Chen F, Hong H, Valdovinos HF, Hernandez R, Shi S, Barnhart TE, Cai W. VEGF(1)(2)(1)-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl Mater Interfaces. 2014;6(23):21677\u201385.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"4","key":"656_CR144","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1039\/c4pp00312h","volume":"14","author":"G Obaid","year":"2015","unstructured":"Obaid G, Chambrier I, Cook MJ, Russell DA. Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles. Photochem Photobiol Sci. 2015;14(4):737\u201347.","journal-title":"Photochem Photobiol Sci"},{"key":"656_CR145","doi-asserted-by":"publisher","first-page":"30076","DOI":"10.1038\/srep30076","volume":"6","author":"JT Jorgensen","year":"2016","unstructured":"Jorgensen JT, Norregaard K, Tian P, Bendix PM, Kjaer A, Oddershede LB. Single particle and PET-based platform for identifying optimal plasmonic nano-heaters for photothermal cancer therapy. Sci Rep. 2016;6:30076.","journal-title":"Sci Rep"},{"issue":"1","key":"656_CR146","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12951-021-00874-9","volume":"19","author":"W Guo","year":"2021","unstructured":"Guo W, Chen Z, Feng X, Shen G, Huang H, Liang Y, Zhao B, Li G, Hu Y. Graphene oxide (GO)-based nanosheets with combined chemo\/photothermal\/photodynamic therapy to overcome gastric cancer (GC) paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP). J Nanobiotechnol. 2021;19(1):146.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"656_CR147","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.nano.2015.10.012","volume":"12","author":"MS Kim","year":"2016","unstructured":"Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12(3):655\u201364.","journal-title":"Nanomedicine"},{"key":"656_CR148","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2017.09.006","volume":"267","author":"AS Wadajkar","year":"2017","unstructured":"Wadajkar AS, Dancy JG, Roberts NB, Connolly NP, Strickland DK, Winkles JA, Woodworth GF, Kim AJ. Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas. J Control Release. 2017;267:144\u201353.","journal-title":"J Control Release"},{"issue":"8","key":"656_CR149","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1049\/mnl.2016.0078","volume":"11","author":"H Xu","year":"2016","unstructured":"Xu H, Wei D, Gai X, Jiang Y. Amine functionalised hydroxyapatite nanoparticles for anti-angiogenesis gene therapy of breast cancer. Micro & Nano Letters. 2016;11(8):416\u20139.","journal-title":"Micro & Nano Letters"},{"issue":"5","key":"656_CR150","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1021\/acs.nanolett.0c05039","volume":"21","author":"Y Yin","year":"2021","unstructured":"Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, Yu S, Nie G, Wang H. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 2021;21(5):2224\u201331.","journal-title":"Nano Lett"},{"key":"656_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117119","volume":"178","author":"R Xue","year":"2024","unstructured":"Xue R, Pan Y, Xia L, Li J. Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance. Biomed Pharmacother. 2024;178: 117119.","journal-title":"Biomed Pharmacother"},{"key":"656_CR152","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtn.2023.03.021","volume":"32","author":"E Martino","year":"2023","unstructured":"Martino E, D\u2019Onofrio N, Anastasio C, Abate M, Zappavigna S, Caraglia M, Balestrieri ML. MicroRNA-nanoparticles against cancer: opportunities and challenges for personalized medicine. Mol Ther Nucleic Acids. 2023;32:371\u201384.","journal-title":"Mol Ther Nucleic Acids"},{"key":"656_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103603","volume":"74","author":"C\u00dc Tun\u00e7","year":"2022","unstructured":"Tun\u00e7 C\u00dc, Aydin O. Co-delivery of Bcl-2 siRNA and doxorubicin through gold nanoparticle-based delivery system for a combined cancer therapy approach. J Drug Deliv Sci Technol. 2022;74: 103603.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"656_CR154","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/neuonc\/nox152","volume":"20","author":"FM Lang","year":"2018","unstructured":"Lang FM, Hossain A, Gumin J, Momin EN, Shimizu Y, Ledbetter D, Shahar T, Yamashita S, Parker Kerrigan B, Fueyo J, et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro Oncol. 2018;20(3):380\u201390.","journal-title":"Neuro Oncol"},{"issue":"21","key":"656_CR155","doi-asserted-by":"publisher","first-page":"13364","DOI":"10.1021\/acs.inorgchem.8b01955","volume":"57","author":"R Abazari","year":"2018","unstructured":"Abazari R, Mahjoub AR, Ataei F, Morsali A, Carpenter-Warren CL, Mehdizadeh K, Slawin AMZ. Chitosan immobilization on bio-MOF nanostructures: a biocompatible pH-responsive nanocarrier for doxorubicin release on MCF-7 cell lines of human breast cancer. Inorg Chem. 2018;57(21):13364\u201379.","journal-title":"Inorg Chem"},{"key":"656_CR156","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.biopha.2016.03.015","volume":"80","author":"G Prabha","year":"2016","unstructured":"Prabha G, Raj V. Formation and characterization of beta-cyclodextrin (beta-CD) - polyethyleneglycol (PEG)\u2014polyethyleneimine (PEI) coated Fe3O4 nanoparticles for loading and releasing 5-Fluorouracil drug. Biomed Pharmacother. 2016;80:173\u201382.","journal-title":"Biomed Pharmacother"},{"key":"656_CR157","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.biomaterials.2015.10.028","volume":"75","author":"L Wen","year":"2016","unstructured":"Wen L, Ding W, Yang S, Xing D. Microwave pumped high-efficient thermoacoustic tumor therapy with single wall carbon nanotubes. Biomaterials. 2016;75:163\u201373.","journal-title":"Biomaterials"},{"issue":"1","key":"656_CR158","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1038\/s41467-019-10893-8","volume":"10","author":"M Hu","year":"2019","unstructured":"Hu M, Wang Y, Xu L, An S, Tang Y, Zhou X, Li J, Liu R, Huang L. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat Commun. 2019;10(1):2993.","journal-title":"Nat Commun"},{"issue":"1","key":"656_CR159","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41467-019-08538-x","volume":"10","author":"X Yu","year":"2019","unstructured":"Yu X, Chen L, Liu J, Dai B, Xu G, Shen G, Luo Q, Zhang Z. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nat Commun. 2019;10(1):574.","journal-title":"Nat Commun"},{"issue":"1","key":"656_CR160","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/btm2.10003","volume":"1","author":"AC Anselmo","year":"2016","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10\u201329.","journal-title":"Bioeng Transl Med"},{"issue":"25","key":"656_CR161","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1056\/NEJMra0912273","volume":"363","author":"BY Kim","year":"2010","unstructured":"Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363(25):2434\u201343.","journal-title":"N Engl J Med"},{"issue":"6","key":"656_CR162","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1021\/mp100228v","volume":"7","author":"T Lammers","year":"2010","unstructured":"Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm. 2010;7(6):1899\u2013912.","journal-title":"Mol Pharm"},{"issue":"4","key":"656_CR163","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1039\/D1EN00017A","volume":"8","author":"LJ Desmond","year":"2021","unstructured":"Desmond LJ, Phan AN, Gentile P. Critical overview on the green synthesis of carbon quantum dots and their application for cancer therapy. Environ Sci Nano. 2021;8(4):848\u201362.","journal-title":"Environ Sci Nano"},{"issue":"1","key":"656_CR164","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-024-01531-y","volume":"17","author":"YJ Kim","year":"2024","unstructured":"Kim YJ, Rho W-Y, Park S-M, Jun B-H. Optical nanomaterial-based detection of biomarkers in liquid biopsy. J Hematol Oncol. 2024;17(1):10.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"656_CR165","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/mi15101181","volume":"15","author":"A Khan","year":"2024","unstructured":"Khan A, Raza F, He N. Nanoscale extracellular vesicle-enabled liquid biopsy: advances and challenges for lung cancer detection. Micromachines. 2024;15(10):1181.","journal-title":"Micromachines"},{"key":"656_CR166","first-page":"1","volume":"8","author":"AN Steward","year":"2024","unstructured":"Steward AN, Fernandez WV. A scoping review of 20\u2013100NM gold nanomaterials for cancer diagnosis. Undergrad Res Nat Clin Sci Technol J. 2024;8:1\u20139.","journal-title":"Undergrad Res Nat Clin Sci Technol J"},{"issue":"6","key":"656_CR167","doi-asserted-by":"publisher","first-page":"660","DOI":"10.7150\/thno.8698","volume":"4","author":"MS Muthu","year":"2014","unstructured":"Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics\u2014application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4(6):660\u201377.","journal-title":"Theranostics"},{"issue":"8","key":"656_CR168","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1039\/C8LC00100F","volume":"18","author":"L Gorgannezhad","year":"2018","unstructured":"Gorgannezhad L, Umer M, Islam MN, Nguyen NT, Shiddiky MJA. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab Chip. 2018;18(8):1174\u201396.","journal-title":"Lab Chip"},{"issue":"1","key":"656_CR169","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s42003-022-03598-0","volume":"5","author":"N He","year":"2022","unstructured":"He N, Thippabhotla S, Zhong C, Greenberg Z, Xu L, Pessetto Z, Godwin AK, Zeng Y, He M. Nano pom-poms prepared exosomes enable highly specific cancer biomarker detection. Commun Biol. 2022;5(1):660.","journal-title":"Commun Biol"},{"issue":"1","key":"656_CR170","doi-asserted-by":"publisher","first-page":"14185","DOI":"10.1038\/s41598-021-93207-7","volume":"11","author":"A Tadimety","year":"2021","unstructured":"Tadimety A, Wu Z, Molinski JH, Beckerman R, Jin C, Zhang L, Palinski TJ, Zhang JXJ. Rational design of on-chip gold plasmonic nanoparticles towards ctDNA screening. Sci Rep. 2021;11(1):14185.","journal-title":"Sci Rep"},{"issue":"19","key":"656_CR171","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/adma.201300081","volume":"25","author":"N Lee","year":"2013","unstructured":"Lee N, Choi SH, Hyeon T. Nano-sized CT contrast agents. Adv Mater. 2013;25(19):2641\u201360.","journal-title":"Adv Mater"},{"key":"656_CR172","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.copbio.2017.01.002","volume":"46","author":"DA Scheinberg","year":"2017","unstructured":"Scheinberg DA, Grimm J, Heller DA, Stater EP, Bradbury M, McDevitt MR. Advances in the clinical translation of nanotechnology. Curr Opin Biotechnol. 2017;46:66\u201373.","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"656_CR173","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.biotechadv.2013.12.009","volume":"32","author":"J Li","year":"2014","unstructured":"Li J, Chang X, Chen X, Gu Z, Zhao F, Chai Z, Zhao Y. Toxicity of inorganic nanomaterials in biomedical imaging. Biotechnol Adv. 2014;32(4):727\u201343.","journal-title":"Biotechnol Adv"},{"issue":"1\u20132","key":"656_CR174","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11010-011-0934-y","volume":"358","author":"AK Patlolla","year":"2011","unstructured":"Patlolla AK, Berry A, Tchounwou PB. Study of hepatotoxicity and oxidative stress in male Swiss-Webster mice exposed to functionalized multi-walled carbon nanotubes. Mol Cell Biochem. 2011;358(1\u20132):189\u201399.","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"656_CR175","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/17435390.2016.1202351","volume":"10","author":"SS Poulsen","year":"2016","unstructured":"Poulsen SS, Jackson P, Kling K, Knudsen KB, Skaug V, Kyjovska ZO, Thomsen BL, Clausen PA, Atluri R, Berthing T, et al. Multi-walled carbon nanotube physicochemical properties predict pulmonary inflammation and genotoxicity. Nanotoxicology. 2016;10(9):1263\u201375.","journal-title":"Nanotoxicology"},{"issue":"1","key":"656_CR176","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12989-016-0166-0","volume":"13","author":"Y Suzuki","year":"2016","unstructured":"Suzuki Y, Tada-Oikawa S, Hayashi Y, Izuoka K, Kataoka M, Ichikawa S, Wu W, Zong C, Ichihara G, Ichihara S. Single- and double-walled carbon nanotubes enhance atherosclerogenesis by promoting monocyte adhesion to endothelial cells and endothelial progenitor cell dysfunction. Part Fibre Toxicol. 2016;13(1):54.","journal-title":"Part Fibre Toxicol"},{"issue":"2","key":"656_CR177","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1021\/acsnano.0c10276","volume":"15","author":"V Mulens-Arias","year":"2021","unstructured":"Mulens-Arias V, Nicolas-Boluda A, Pinto A, Balfourier A, Carn F, Silva AKA, Pocard M, Gazeau F. Tumor-selective immune-active mild hyperthermia associated with chemotherapy in colon peritoneal metastasis by photoactivation of fluorouracil-gold nanoparticle complexes. ACS Nano. 2021;15(2):3330\u201348.","journal-title":"ACS Nano"},{"issue":"12","key":"656_CR178","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.7150\/thno.25220","volume":"8","author":"W Xie","year":"2018","unstructured":"Xie W, Guo Z, Gao F, Gao Q, Wang D, Liaw BS, Cai Q, Sun X, Wang X, Zhao L. Shape-, size- and structure-controlled synthesis and biocompatibility of iron oxide nanoparticles for magnetic theranostics. Theranostics. 2018;8(12):3284\u2013307.","journal-title":"Theranostics"},{"issue":"1","key":"656_CR179","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12989-016-0168-y","volume":"13","author":"L Ou","year":"2016","unstructured":"Ou L, Song B, Liang H, Liu J, Feng X, Deng B, Sun T, Shao L. Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms. Part Fibre Toxicol. 2016;13(1):57.","journal-title":"Part Fibre Toxicol"},{"issue":"1","key":"656_CR180","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41368-021-00132-6","volume":"13","author":"L Wang","year":"2021","unstructured":"Wang L, Liu S, Ren C, Xiang S, Li D, Hao X, Ni S, Chen Y, Zhang K, Sun H. Construction of hollow polydopamine nanoparticle based drug sustainable release system and its application in bone regeneration. Int J Oral Sci. 2021;13(1):27.","journal-title":"Int J Oral Sci"},{"issue":"5","key":"656_CR181","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","volume":"20","author":"LA Low","year":"2021","unstructured":"Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"656_CR182","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/aivt.2015.0029","volume":"2","author":"HH Middelkamp","year":"2016","unstructured":"Middelkamp HH, van der Meer AD, Hummel JM, Stamatialis DF, Mummery CL, Passier R. Organs-on-chips in drug development: the importance of involving stakeholders in early health technology assessment. Appl Vitro Toxicol. 2016;2(2):74\u201381.","journal-title":"Appl Vitro Toxicol"},{"issue":"6","key":"656_CR183","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41565-023-01323-4","volume":"18","author":"M Zhu","year":"2023","unstructured":"Zhu M, Zhuang J, Li Z, Liu Q, Zhao R, Gao Z, Midgley AC, Qi T, Tian J, Zhang Z, et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures. Nat Nanotechnol. 2023;18(6):657\u201366.","journal-title":"Nat Nanotechnol"},{"key":"656_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114708","volume":"194","author":"M Kumar","year":"2023","unstructured":"Kumar M, Kulkarni P, Liu S, Chemuturi N, Shah DK. Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles. Adv Drug Deliv Rev. 2023;194: 114708.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"656_CR185","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2174\/2211738507666190925112942","volume":"7","author":"G Anderluzzi","year":"2019","unstructured":"Anderluzzi G, Lou G, Su Y, Perrie Y. Scalable manufacturing processes for solid lipid nanoparticles. Pharm Nanotechnol. 2019;7(6):444\u201359.","journal-title":"Pharm Nanotechnol"},{"issue":"22","key":"656_CR186","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/pmic.201300282","volume":"13","author":"H Kalra","year":"2013","unstructured":"Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, Hulett MD, Mathivanan S. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics. 2013;13(22):3354\u201364.","journal-title":"Proteomics"},{"key":"656_CR187","doi-asserted-by":"publisher","first-page":"204173142311746","DOI":"10.1177\/20417314231174609","volume":"14","author":"S Williams","year":"2023","unstructured":"Williams S, Fernandez-Rhodes M, Law A, Peacock B, Lewis MP, Davies OG. Comparison of extracellular vesicle isolation processes for therapeutic applications. J Tissue Eng. 2023;14:20417314231174610.","journal-title":"J Tissue Eng"},{"issue":"64","key":"656_CR188","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/scitranslmed.3001385","volume":"3","author":"M Murakami","year":"2011","unstructured":"Murakami M, Cabral H, Matsumoto Y, Wu S, Kano MR, Yamori T, Nishiyama N, Kataoka K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med. 2011;3(64):642\u2013642.","journal-title":"Sci Transl Med"},{"issue":"1","key":"656_CR189","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40580-022-00313-x","volume":"9","author":"R Singh","year":"2022","unstructured":"Singh R, Sharma A, Saji J, Umapathi A, Kumar S, Daima HK. Smart nanomaterials for cancer diagnosis and treatment. Nano Converg. 2022;9(1):21.","journal-title":"Nano Converg"},{"key":"656_CR190","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.canlet.2018.01.024","volume":"418","author":"Y Sun","year":"2018","unstructured":"Sun Y, Miao H, Ma S, Zhang L, You C, Tang F, Yang C, Tian X, Wang F, Luo Y, et al. FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells in vivo and in vitro. Cancer Lett. 2018;418:27\u201340.","journal-title":"Cancer Lett"},{"issue":"1","key":"656_CR191","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12951-022-01364-2","volume":"20","author":"N Kaushik","year":"2022","unstructured":"Kaushik N, Borkar SB, Nandanwar SK, Panda PK, Choi EH, Kaushik NK. Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnology. 2022;20(1):152.","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"656_CR192","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12951-022-01759-1","volume":"21","author":"P Zhang","year":"2023","unstructured":"Zhang P, Cui Y, Wang J, Cheng J, Zhu L, Liu C, Yue S, Pang R, Guan J, Xie B, et al. Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma. Journal of Nanobiotechnology. 2023;21(1):4.","journal-title":"Journal of Nanobiotechnology"},{"issue":"Pt A","key":"656_CR193","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"656_CR194","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fbioe.2019.00415","volume":"7","author":"OS Thomas","year":"2019","unstructured":"Thomas OS, Weber W. Overcoming physiological barriers to nanoparticle delivery-are we there yet? Front Bioeng Biotechnol. 2019;7:415.","journal-title":"Front Bioeng Biotechnol"},{"issue":"22","key":"656_CR195","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1021\/acs.jpcb.5b01351","volume":"119","author":"M Dzieciuch","year":"2015","unstructured":"Dzieciuch M, Rissanen S, Szydlowska N, Bunker A, Kumorek M, Jamroz D, Vattulainen I, Nowakowska M, Rog T, Kepczynski M. PEGylated liposomes as carriers of hydrophobic porphyrins. J Phys Chem B. 2015;119(22):6646\u201357.","journal-title":"J Phys Chem B"},{"issue":"6","key":"656_CR196","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1166\/jbn.2015.1865","volume":"11","author":"W She","year":"2015","unstructured":"She W, Pan D, Luo K, He B, Cheng G, Zhang C, Gu Z. PEGylated dendrimer-doxorubicin cojugates as pH-sensitive drug delivery systems: synthesis and in vitro characterization. J Biomed Nanotechnol. 2015;11(6):964\u201378.","journal-title":"J Biomed Nanotechnol"},{"issue":"8","key":"656_CR197","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, Wragg KM, Subbarao K, Nguyen THO, Rowntree LC, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16(8):11769\u201380.","journal-title":"ACS Nano"},{"issue":"2","key":"656_CR198","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/polym12020298","volume":"12","author":"TT Hoang Thi","year":"2020","unstructured":"Hoang Thi TT, Pilkington EH, Nguyen DH, Lee JS, Park KD, Truong NP. The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation. Polymers. 2020;12(2):298.","journal-title":"Polymers"},{"issue":"9","key":"656_CR199","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"BM Chen","year":"2021","unstructured":"Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano. 2021;15(9):14022\u201348.","journal-title":"ACS Nano"},{"issue":"1","key":"656_CR200","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1039\/C6NR07353K","volume":"9","author":"L Sanchez","year":"2017","unstructured":"Sanchez L, Yi Y, Yu Y. Effect of partial PEGylation on particle uptake by macrophages. Nanoscale. 2017;9(1):288\u201397.","journal-title":"Nanoscale"},{"issue":"12","key":"656_CR201","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1039\/D2BM00181K","volume":"10","author":"JA Mills","year":"2022","unstructured":"Mills JA, Liu F, Jarrett TR, Fletcher NL, Thurecht KJ. Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation. Biomater Sci. 2022;10(12):3029\u201353.","journal-title":"Biomater Sci"},{"key":"656_CR202","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.2147\/IJN.S387681","volume":"17","author":"J Ye","year":"2022","unstructured":"Ye J, Li R, Cheng J, Liu D, Yang Y, Wang H, Xu X, Li L, Ma P, Liu Y. Comparative colloidal stability of commercial amphotericin B nanoformulations using dynamic and static multiple light scattering techniques. Int J Nanomedicine. 2022;17:6047\u201364.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"656_CR203","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12951-021-00946-w","volume":"19","author":"J Ye","year":"2021","unstructured":"Ye J, Li R, Yang Y, Dong W, Wang Y, Wang H, Sun T, Li L, Shen Q, Qin C, et al. Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations. J Nanobiotechnology. 2021;19(1):199.","journal-title":"J Nanobiotechnology"},{"key":"656_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106369","volume":"181","author":"M Ruzycka-Ayoush","year":"2023","unstructured":"Ruzycka-Ayoush M, Nowicka AM, Kowalczyk A, Gluchowska A, Targonska A, Mosieniak G, Sobczak K, Donten M, Grudzinski IP. Exosomes derived from lung cancer cells: Isolation, characterization, and stability studies. Eur J Pharm Sci. 2023;181: 106369.","journal-title":"Eur J Pharm Sci"},{"issue":"22","key":"656_CR205","doi-asserted-by":"publisher","first-page":"12261","DOI":"10.3390\/ijms222212261","volume":"22","author":"MR Mollaeva","year":"2021","unstructured":"Mollaeva MR, Yabbarov N, Sokol M, Chirkina M, Mollaev MD, Zabolotskii A, Seregina I, Bolshov M, Kaplun A, Nikolskaya E. Optimization, characterization and pharmacokinetic study of meso-tetraphenylporphyrin metal complex-loaded PLGA nanoparticles. Int J Mol Sci. 2021;22(22):12261.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"656_CR206","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics11100489","volume":"11","author":"T Feczko","year":"2019","unstructured":"Feczko T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rodel F, Vogl TJ, Wacker MG. Theranostic sorafenib-loaded polymeric nanocarriers manufactured by enhanced gadolinium conjugation techniques. Pharmaceutics. 2019;11(10):489.","journal-title":"Pharmaceutics"},{"key":"656_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119566","volume":"586","author":"CB Roces","year":"2020","unstructured":"Roces CB, Port EC, Daskalakis NN, Watts JA, Aylott JW, Halbert GW, Perrie Y. Rapid scale-up and production of active-loaded PEGylated liposomes. Int J Pharm. 2020;586: 119566.","journal-title":"Int J Pharm"},{"issue":"4","key":"656_CR208","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/pharmaceutics10040263","volume":"10","author":"H Zhong","year":"2018","unstructured":"Zhong H, Chan G, Hu Y, Hu H, Ouyang D. A comprehensive map of FDA-approved pharmaceutical products. Pharmaceutics. 2018;10(4):263.","journal-title":"Pharmaceutics"},{"issue":"8","key":"656_CR209","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","volume":"14","author":"PS Gill","year":"1996","unstructured":"Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol. 1996;14(8):2353\u201364.","journal-title":"J Clin Oncol"},{"issue":"11","key":"656_CR210","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/S0149-2918(02)80087-X","volume":"24","author":"R Perez-Marreno","year":"2002","unstructured":"Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther. 2002;24(11):1902\u201314.","journal-title":"Clin Ther"},{"issue":"3","key":"656_CR211","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0022-5347(05)64625-3","volume":"168","author":"FM Chu","year":"2002","unstructured":"Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002;168(3):1199\u2013203.","journal-title":"J Urol"},{"issue":"5","key":"656_CR212","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","volume":"75","author":"LJ Ettinger","year":"1995","unstructured":"Ettinger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995;75(5):1176\u201381.","journal-title":"Cancer"},{"issue":"8","key":"656_CR213","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","volume":"12","author":"PA Dinndorf","year":"2007","unstructured":"Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991\u20138.","journal-title":"Oncologist"},{"issue":"10","key":"656_CR214","doi-asserted-by":"publisher","first-page":"9925","DOI":"10.1021\/nn501069c","volume":"8","author":"J Li","year":"2014","unstructured":"Li J, Cai P, Shalviri A, Henderson JT, He C, Foltz WD, Prasad P, Brodersen PM, Chen Y, DaCosta R, et al. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano. 2014;8(10):9925\u201340.","journal-title":"ACS Nano"},{"issue":"4","key":"656_CR215","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/bc300632w","volume":"24","author":"X Wei","year":"2013","unstructured":"Wei X, Senanayake TH, Warren G, Vinogradov SV. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem. 2013;24(4):658\u201368.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"656_CR216","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/smll.201602225","volume":"13","author":"X Yao","year":"2017","unstructured":"Yao X, Niu X, Ma K, Huang P, Grothe J, Kaskel S, Zhu Y. Graphene quantum dots-capped magnetic mesoporous silica nanoparticles as a multifunctional platform for controlled drug delivery, magnetic hyperthermia, and photothermal therapy. Small. 2017;13(2):65.","journal-title":"Small"},{"issue":"23","key":"656_CR217","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-16-2186","volume":"23","author":"L Gu","year":"2017","unstructured":"Gu L, Deng ZJ, Roy S, Hammond PT. A combination RNAi-chemotherapy layer-by-layer nanoparticle for systemic targeting of KRAS\/P53 with cisplatin to treat non-small cell lung cancer. Clin Cancer Res. 2017;23(23):7312\u201323.","journal-title":"Clin Cancer Res"},{"key":"656_CR218","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jcis.2017.02.006","volume":"496","author":"O Penon","year":"2017","unstructured":"Penon O, Marin MJ, Russell DA, Perez-Garcia L. Water soluble, multifunctional antibody-porphyrin gold nanoparticles for targeted photodynamic therapy. J Colloid Interface Sci. 2017;496:100\u201310.","journal-title":"J Colloid Interface Sci"},{"issue":"2","key":"656_CR219","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.nano.2017.11.010","volume":"14","author":"N Amreddy","year":"2018","unstructured":"Amreddy N, Babu A, Panneerselvam J, Srivastava A, Muralidharan R, Chen A, Zhao YD, Munshi A, Ramesh R. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018;14(2):373\u201384.","journal-title":"Nanomedicine"},{"key":"656_CR220","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jconrel.2017.11.026","volume":"269","author":"JS Kim","year":"2018","unstructured":"Kim JS, Shin DH, Kim JS. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release. 2018;269:245\u201357.","journal-title":"J Control Release"},{"issue":"1","key":"656_CR221","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1021\/acsnano.8b06164","volume":"13","author":"X Liu","year":"2019","unstructured":"Liu X, Jiang J, Chan R, Ji Y, Lu J, Liao YP, Okene M, Lin J, Lin P, Chang CH, et al. Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer. ACS Nano. 2019;13(1):38\u201353.","journal-title":"ACS Nano"},{"key":"656_CR222","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.2147\/IJN.S214923","volume":"14","author":"M Ebadi","year":"2019","unstructured":"Ebadi M, Saifullah B, Buskaran K, Hussein MZ, Fakurazi S. Synthesis and properties of magnetic nanotheranostics coated with polyethylene glycol\/5-fluorouracil\/layered double hydroxide. Int J Nanomed. 2019;14:6661\u201378.","journal-title":"Int J Nanomed"},{"issue":"2","key":"656_CR223","first-page":"1365","volume":"13","author":"P Kadiyala","year":"2019","unstructured":"Kadiyala P, Li D, Nunez FM, Altshuler D, Doherty R, Kuai R, Yu M, Kamran N, Edwards M, Moon JJ, et al. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano. 2019;13(2):1365\u201384.","journal-title":"ACS Nano"},{"issue":"1","key":"656_CR224","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s11671-019-2924-z","volume":"14","author":"R Zhang","year":"2019","unstructured":"Zhang R, Zhang Y, Tan J, Wang H, Zhang G, Li N, Meng Z, Zhang F, Chang J, Wang R. Antitumor effect of (131)I-labeled anti-VEGFR2 targeted mesoporous silica nanoparticles in anaplastic thyroid cancer. Nanoscale Res Lett. 2019;14(1):96.","journal-title":"Nanoscale Res Lett"},{"issue":"1","key":"656_CR225","doi-asserted-by":"publisher","first-page":"21521","DOI":"10.1038\/s41598-020-76504-5","volume":"10","author":"M Ebadi","year":"2020","unstructured":"Ebadi M, Bullo S, Buskara K, Hussein MZ, Fakurazi S, Pastorin G. Release of a liver anticancer drug, sorafenib from its PVA\/LDH- and PEG\/LDH-coated iron oxide nanoparticles for drug delivery applications. Sci Rep. 2020;10(1):21521.","journal-title":"Sci Rep"},{"key":"656_CR226","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jconrel.2020.07.025","volume":"326","author":"N Tsakiris","year":"2020","unstructured":"Tsakiris N, Fauvet F, Ruby S, Puisieux A, Paquot A, Muccioli GG, Vigneron AM, Preat V. Combined nanomedicines targeting colorectal cancer stem cells and cancer cells. J Control Release. 2020;326:387\u201395.","journal-title":"J Control Release"},{"issue":"9","key":"656_CR227","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1049\/iet-nbt.2020.0101","volume":"14","author":"A Khan","year":"2020","unstructured":"Khan A, Kumar Sahu N. Folate encapsulation in PEG-diamine grafted mesoporous Fe(3)O(4) nanoparticles for hyperthermia and in vitro assessment. IET Nanobiotechnol. 2020;14(9):881\u20138.","journal-title":"IET Nanobiotechnol"},{"issue":"45","key":"656_CR228","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/ab8b0e","volume":"31","author":"K Asghar","year":"2020","unstructured":"Asghar K, Qasim M, Dharmapuri G, Das D. Thermoresponsive polymer gated and superparamagnetic nanoparticle embedded hollow mesoporous silica nanoparticles as smart multifunctional nanocarrier for targeted and controlled delivery of doxorubicin. Nanotechnology. 2020;31(45): 455604.","journal-title":"Nanotechnology"},{"key":"656_CR229","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2147\/IJN.S220057","volume":"15","author":"L Ou","year":"2020","unstructured":"Ou L, Sun T, Liu M, Zhang Y, Zhou Z, Zhan X, Lu L, Zhao Q, Lai R, Shao L. Efficient miRNA inhibitor delivery with graphene oxide-polyethylenimine to inhibit oral squamous cell carcinoma. Int J Nanomedicine. 2020;15:1569\u201383.","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"656_CR230","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1208\/s12249-020-01743-8","volume":"21","author":"N Chowdhury","year":"2020","unstructured":"Chowdhury N, Chaudhry S, Hall N, Olverson G, Zhang QJ, Mandal T, Dash S, Kundu A. Targeted delivery of doxorubicin liposomes for Her-2+ breast cancer treatment. AAPS PharmSciTech. 2020;21(6):202.","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"656_CR231","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ijms21113742","volume":"21","author":"A Crous","year":"2020","unstructured":"Crous A, Abrahamse H. Effective gold nanoparticle-antibody-mediated drug delivery for photodynamic therapy of lung cancer stem cells. Int J Mol Sci. 2020;21(11):30.","journal-title":"Int J Mol Sci"},{"key":"656_CR232","doi-asserted-by":"crossref","unstructured":"Nunes SS, Miranda SE, de Oliveira Silva J, Fernandes RS, de Alc\u00e2ntara Lemos J, de Aguiar Ferreira C, Townsend DM, Cassali GD, Oliveira MC, de Barros AL. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment. Biomed Pharmacother, 2021. 144: 112317.","DOI":"10.1016\/j.biopha.2021.112317"},{"key":"656_CR233","doi-asserted-by":"publisher","first-page":"128935","DOI":"10.1016\/j.colsurfa.2022.128935","volume":"645","author":"MT Luiz","year":"2022","unstructured":"Luiz MT, Dutra JAP, Ribeiro TDC, Carvalho GC, S\u00e1bio RM, Marchetti JM, Chorilli M. Folic acid-modified curcumin-loaded liposomes for breast cancer therapy. Colloid Surf A. 2022;645:128935.","journal-title":"Colloid Surf A"},{"issue":"14","key":"656_CR234","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules27144634","volume":"27","author":"B Honarvari","year":"2022","unstructured":"Honarvari B, Karimifard S, Akhtari N, Mehrarya M, Moghaddam ZS, Ansari MJ, Jalil AT, Matencio A, Trotta F, Yeganeh FE, et al. Folate-targeted curcumin-loaded niosomes for site-specific delivery in breast cancer treatment: in silico and in vitro study. Molecules. 2022;27(14):4.","journal-title":"Molecules"},{"key":"656_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112586","volume":"134","author":"MRM Radzi","year":"2022","unstructured":"Radzi MRM, Johari NA, Zawawi W, Zawawi NA, Latiff NA, Malek N, Wahab AA, Salim MI, Jemon K. In vivo evaluation of oxidized multiwalled-carbon nanotubes-mediated hyperthermia treatment for breast cancer. Biomater Adv. 2022;134: 112586.","journal-title":"Biomater Adv"},{"issue":"1","key":"656_CR236","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/21691401.2023.2233568","volume":"51","author":"B Mkhobongo","year":"2023","unstructured":"Mkhobongo B, Chandran R, Abrahamse H. Impact of aluminium phthalocyanine nanoconjugate on melanoma stem cells. Artif Cells Nanomed Biotechnol. 2023;51(1):334\u201345.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"8","key":"656_CR237","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/pharmaceutics15082158","volume":"15","author":"SS Ilangovan","year":"2023","unstructured":"Ilangovan SS, Mahanty B, Perumal V, Sen S. modulating the effect of beta-sitosterol conjugated with magnetic nanocarriers to inhibit EGFR and Met Receptor Cross Talk. Pharmaceutics. 2023;15(8):2158.","journal-title":"Pharmaceutics"},{"key":"656_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114122","volume":"243","author":"A Taghikhani","year":"2024","unstructured":"Taghikhani A, Babazadeh M, Davaran S, Ghasemi E. Facile preparation of a pH-sensitive biocompatible nanocarrier based on magnetic layered double hydroxides\/Cu MOFs-chitosan crosslinked small ka, Cyrillic-carrageenan for controlled doxorubicin delivery to breast cancer cells. Colloids Surf B Biointerfaces. 2024;243: 114122.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"656_CR239","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/21691401.2024.2357693","volume":"52","author":"NWN Simelane","year":"2024","unstructured":"Simelane NWN, Abrahamse H. Actively targeted photodynamic therapy in multicellular colorectal cancer spheroids via functionalised gold nanoparticles. Artif Cells Nanomed Biotechnol. 2024;52(1):309\u201320.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"3","key":"656_CR240","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41587-023-01796-7","volume":"42","author":"D Ji","year":"2024","unstructured":"Ji D, Zhang Y, Sun J, Zhang B, Ma W, Cheng B, Wang X, Li Y, Mu Y, Xu H, et al. An engineered influenza virus to deliver antigens for lung cancer vaccination. Nat Biotechnol. 2024;42(3):518\u201328.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"656_CR241","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1021\/acsbiomaterials.6b00241","volume":"2","author":"CP Silveira","year":"2016","unstructured":"Silveira CP, Apolinario LM, Favaro WJ, Paula AJ, Duran N. Doxorubicin-functionalized silica nanoparticles incorporated into a thermoreversible hydrogel and intraperitoneally administered result in high prostate antitumor activity and reduced cardiotoxicity of doxorubicin. ACS Biomater Sci Eng. 2016;2(7):1190\u20139.","journal-title":"ACS Biomater Sci Eng"},{"issue":"11","key":"656_CR242","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.1021\/nn4047925","volume":"7","author":"ZJ Deng","year":"2013","unstructured":"Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano. 2013;7(11):9571\u201384.","journal-title":"ACS Nano"},{"issue":"2","key":"656_CR243","doi-asserted-by":"publisher","DOI":"10.1002\/agt2.314","volume":"4","author":"G Yang","year":"2023","unstructured":"Yang G, Liu Y, Jin S, Hui Y, Wang X, Xu L, Chen D, Weitz D, Zhao CX. Phase separation-induced nanoprecipitation for making polymer nanoparticles with high drug loading: special collection: distinguished Australian researchers. Aggregate. 2023;4(2): e314.","journal-title":"Aggregate"},{"key":"656_CR244","first-page":"5249","volume":"7","author":"R Liu","year":"2012","unstructured":"Liu R, Lai Y, He B, Li Y, Wang G, Chang S, Gu Z. Supramolecular nanoparticles generated by the self-assembly of polyrotaxanes for antitumor drug delivery. Int J Nanomedicine. 2012;7:5249\u201358.","journal-title":"Int J Nanomedicine"},{"issue":"1\u20132","key":"656_CR245","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijpharm.2010.10.015","volume":"403","author":"Y Cirpanli","year":"2011","unstructured":"Cirpanli Y, Allard E, Passirani C, Bilensoy E, Lemaire L, Calis S, Benoit JP. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm. 2011;403(1\u20132):201\u20136.","journal-title":"Int J Pharm"},{"issue":"1","key":"656_CR246","doi-asserted-by":"publisher","first-page":"16517","DOI":"10.1038\/s41598-017-16878-1","volume":"7","author":"A Hafeez","year":"2017","unstructured":"Hafeez A, Kazmi I. Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. Sci Rep. 2017;7(1):16517.","journal-title":"Sci Rep"},{"issue":"26","key":"656_CR247","first-page":"29641","volume":"12","author":"J Li","year":"2020","unstructured":"Li J, Lee MMS, Li H, Tong C, Huang J, Yan Y, Wang D, Tang BZ. Programmed self-assembly of protein-coated aie-featured nanoparticles with dual imaging and targeted therapy to cancer cells. ACS Appl Mater Interfaces. 2020;12(26):29641\u20139.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"656_CR248","doi-asserted-by":"publisher","first-page":"8423","DOI":"10.1021\/acsnano.8b03900","volume":"12","author":"Q Dai","year":"2018","unstructured":"Dai Q, Wilhelm S, Ding D, Syed AM, Sindhwani S, Zhang Y, Chen YY, MacMillan P, Chan WCW. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano. 2018;12(8):8423\u201335.","journal-title":"ACS Nano"},{"issue":"3","key":"656_CR249","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/gels9030201","volume":"9","author":"A Nawaz","year":"2023","unstructured":"Nawaz A, Latif MS, Shah MKA, Elsayed TM, Ahmad S, Khan HA. Formulation and characterization of ethyl cellulose-based patches containing curcumin-chitosan nanoparticles for the possible management of inflammation via skin delivery. Gels. 2023;9(3):3.","journal-title":"Gels"},{"issue":"38","key":"656_CR250","doi-asserted-by":"publisher","first-page":"11337","DOI":"10.1002\/slct.201901728","volume":"4","author":"AG Tanwar","year":"2019","unstructured":"Tanwar AG, Date PB, Ottoor DP. In Vitro investigation of controlled release of ciprofloxacin and its \u03b2-cyclodextrin inclusion complex from gelatin grafted poly (vinyl alcohol)(GPVA) nanoparticles. ChemistrySelect. 2019;4(38):11337\u201345.","journal-title":"ChemistrySelect"},{"issue":"12","key":"656_CR251","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202006484","volume":"17","author":"F Oroojalian","year":"2021","unstructured":"Oroojalian F, Beygi M, Baradaran B, Mokhtarzadeh A, Shahbazi MA. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021;17(12): e2006484.","journal-title":"Small"},{"issue":"3","key":"656_CR252","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.nano.2013.09.011","volume":"10","author":"JP Almeida","year":"2014","unstructured":"Almeida JP, Figueroa ER, Drezek RA. Gold nanoparticle mediated cancer immunotherapy. Nanomedicine. 2014;10(3):503\u201314.","journal-title":"Nanomedicine"},{"issue":"5","key":"656_CR253","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1021\/nn301282m","volume":"6","author":"K Huang","year":"2012","unstructured":"Huang K, Ma H, Liu J, Huo S, Kumar A, Wei T, Zhang X, Jin S, Gan Y, Wang PC, et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano. 2012;6(5):4483\u201393.","journal-title":"ACS Nano"},{"issue":"1","key":"656_CR254","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15171\/apb.2018.010","volume":"8","author":"F Madani","year":"2018","unstructured":"Madani F, Esnaashari SS, Mujokoro B, Dorkoosh F, Khosravani M, Adabi M. Investigation of effective parameters on size of paclitaxel loaded PLGA nanoparticles. Adv Pharm Bull. 2018;8(1):77\u201384.","journal-title":"Adv Pharm Bull"},{"issue":"3","key":"656_CR255","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004142","volume":"11","author":"F Fu","year":"2015","unstructured":"Fu F, Nowak MA, Bonhoeffer S. Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol. 2015;11(3): e1004142.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"656_CR256","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10439-018-02146-4","volume":"47","author":"HA Miller","year":"2019","unstructured":"Miller HA, Frieboes HB. Evaluation of drug-loaded gold nanoparticle cytotoxicity as a function of tumor vasculature-induced tissue heterogeneity. Ann Biomed Eng. 2019;47(1):257\u201371.","journal-title":"Ann Biomed Eng"},{"issue":"1","key":"656_CR257","doi-asserted-by":"publisher","first-page":"23","DOI":"10.30714\/j-ebr.2021165779","volume":"4","author":"H Akbaba","year":"2021","unstructured":"Akbaba H, Ozder M. Optimization and screening of solid lipid nanoparticle production for gene delivery by factorial design and response surface methodology. Exp Biomed Res. 2021;4(1):23\u201337.","journal-title":"Exp Biomed Res"},{"issue":"8","key":"656_CR258","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/nano10081430","volume":"10","author":"I Nelissen","year":"2020","unstructured":"Nelissen I, Haase A, Anguissola S, Rocks L, Jacobs A, Willems H, Riebeling C, Luch A, Piret JP, Toussaint O, et al. Improving quality in nanoparticle-induced cytotoxicity testing by a tiered inter-laboratory comparison study. Nanomaterials. 2020;10(8):2.","journal-title":"Nanomaterials"},{"issue":"9","key":"656_CR259","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s13346-022-01203-9","volume":"12","author":"KM Eder","year":"2022","unstructured":"Eder KM, Marzi A, Wagbo AM, Vermeulen JP, de la Fonteyne-Blankestijn LJJ, Rosslein M, Ossig R, Klinkenberg G, Vandebriel RJ, Schnekenburger J. Standardization of an in vitro assay matrix to assess cytotoxicity of organic nanocarriers: a pilot interlaboratory comparison. Drug Deliv Transl Res. 2022;12(9):2187\u2013206.","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"656_CR260","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202104632","volume":"18","author":"X Li","year":"2022","unstructured":"Li X, Montague EC, Pollinzi A, Lofts A, Hoare T. Design of smart size-, surface-, and shape-switching nanoparticles to improve therapeutic efficacy. Small. 2022;18(6): e2104632.","journal-title":"Small"},{"issue":"11","key":"656_CR261","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3390\/nano10112186","volume":"10","author":"JA Damasco","year":"2020","unstructured":"Damasco JA, Ravi S, Perez JD, Hagaman DE, Melancon MP. Understanding Nanoparticle Toxicity to Direct a Safe-by-Design Approach in Cancer Nanomedicine. Nanomaterials. 2020;10(11):2186.","journal-title":"Nanomaterials"},{"issue":"1","key":"656_CR262","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2133\/dmpk.DMPK-12-RV-099","volume":"28","author":"IY Gong","year":"2013","unstructured":"Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet. 2013;28(1):4\u201318.","journal-title":"Drug Metab Pharmacokinet"},{"key":"656_CR263","unstructured":"Okunola A, Ahsun A, Temitope A. Strategies for effective resource allocation in nanoparticle technology projects in healthcare. 2024."},{"issue":"3","key":"656_CR264","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/anie.201804882","volume":"58","author":"X Duan","year":"2019","unstructured":"Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed Engl. 2019;58(3):670\u201380.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"22","key":"656_CR265","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.2174\/1381612821666150531165059","volume":"21","author":"JY Yhee","year":"2015","unstructured":"Yhee JY, Son S, Lee H, Kim K. Nanoparticle-based combination therapy for cancer treatment. Curr Pharm Des. 2015;21(22):3158\u201366.","journal-title":"Curr Pharm Des"},{"issue":"22","key":"656_CR266","doi-asserted-by":"publisher","first-page":"14145","DOI":"10.1021\/acsnano.3c03409","volume":"18","author":"P Dosta","year":"2024","unstructured":"Dosta P, Dion MZ, Prado M, Hurtado P, Riojas-Javelly CJ, Cryer AM, Soria Y, Andrews Interiano N, Munoz-Taboada G, Artzi N. Matrix metalloproteinase- and pH-sensitive nanoparticle system enhances drug retention and penetration in glioblastoma. ACS Nano. 2024;18(22):14145\u201360.","journal-title":"ACS Nano"},{"issue":"9","key":"656_CR267","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1049\/iet-nbt.2020.0101","volume":"14","author":"A Khan","year":"2020","unstructured":"Khan A, Kumar Sahu N. Folate encapsulation in PEG-diamine grafted mesoporous Fe3 O4 nanoparticles for hyperthermia and in vitro assessment. IET Nanobiotechnol. 2020;14(9):881\u20138.","journal-title":"IET Nanobiotechnol"},{"issue":"1","key":"656_CR268","doi-asserted-by":"publisher","first-page":"19939","DOI":"10.1038\/s41598-019-56466-z","volume":"9","author":"T Zhang","year":"2019","unstructured":"Zhang T, Trauger SA, Vidoudez C, Doane KP, Pluimer BR, Peterson RT. Parallel Reaction Monitoring reveals structure-specific ceramide alterations in the zebrafish. Sci Rep. 2019;9(1):19939.","journal-title":"Sci Rep"},{"key":"656_CR269","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2021.06.016","volume":"336","author":"B Halamoda-Kenzaoui","year":"2021","unstructured":"Halamoda-Kenzaoui B, Vandebriel RJ, Howarth A, Siccardi M, David CAW, Liptrott NJ, Santin M, Borgos SE, Bremer-Hoffmann S, Caputo F. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation. J Control Release. 2021;336:192\u2013206.","journal-title":"J Control Release"},{"issue":"1\u20132","key":"656_CR270","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ijpharm.2011.07.033","volume":"419","author":"U Katragadda","year":"2011","unstructured":"Katragadda U, Teng Q, Rayaprolu BM, Chandran T, Tan C. Multi-drug delivery to tumor cells via micellar nanocarriers. Int J Pharm. 2011;419(1\u20132):281\u20136.","journal-title":"Int J Pharm"},{"issue":"16","key":"656_CR271","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules25163731","volume":"25","author":"A Zielinska","year":"2020","unstructured":"Zielinska A, Carreiro F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, Lucarini M, Eder P, Silva AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):1.","journal-title":"Molecules"},{"key":"656_CR272","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lfs.2019.01.056","volume":"220","author":"Z Jiang","year":"2019","unstructured":"Jiang Z, Shan K, Song J, Liu J, Rajendran S, Pugazhendhi A, Jacob JA, Chen B. Toxic effects of magnetic nanoparticles on normal cells and organs. Life Sci. 2019;220:156\u201361.","journal-title":"Life Sci"},{"issue":"9","key":"656_CR273","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.tips.2022.05.001","volume":"43","author":"GH Zhu","year":"2022","unstructured":"Zhu GH, Gray ABC, Patra HK. Nanomedicine: controlling nanoparticle clearance for translational success. Trends Pharmacol Sci. 2022;43(9):709\u201311.","journal-title":"Trends Pharmacol Sci"},{"key":"656_CR274","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/IJN.S123839","volume":"12","author":"Y Qin","year":"2017","unstructured":"Qin Y, Li S, Zhao G, Fu X, Xie X, Huang Y, Cheng X, Wei J, Liu H, Lai Z. Long-term intravenous administration of carboxylated single-walled carbon nanotubes induces persistent accumulation in the lungs and pulmonary fibrosis via the nuclear factor-kappa B pathway. Int J Nanomed. 2017;12:263\u201377.","journal-title":"Int J Nanomed"},{"issue":"17","key":"656_CR275","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/21\/17\/175101","volume":"21","author":"D Zhang","year":"2010","unstructured":"Zhang D, Deng X, Ji Z, Shen X, Dong L, Wu M, Gu T, Liu Y. Long-term hepatotoxicity of polyethylene-glycol functionalized multi-walled carbon nanotubes in mice. Nanotechnology. 2010;21(17): 175101.","journal-title":"Nanotechnology"},{"issue":"1","key":"656_CR276","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/nl801828z","volume":"9","author":"A Erdely","year":"2009","unstructured":"Erdely A, Hulderman T, Salmen R, Liston A, Zeidler-Erdely PC, Schwegler-Berry D, Castranova V, Koyama S, Kim YA, Endo M, et al. Cross-talk between lung and systemic circulation during carbon nanotube respiratory exposure. Potential biomarkers. Nano Lett. 2009;9(1):36\u201343.","journal-title":"Nano Lett"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00656-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:03:47Z","timestamp":1747649027000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00656-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":276,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00656-1","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors permit the\n                      Journal of Hematology and Oncology\n                      to publish this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.M.T declares grants (for institution) from OBI Pharma USA, Inc., Macrogenics, 7 Hills Pharma, Agenus, the Parker Institute for Cancer Immunotherapy, Tachyon, Tempus, Tvardi, IMMATICS, Novocure, Orionis, AbbVie, Vividion, Anaveon; and has consulting\/advisory roles for NEX-I, BrYet, Macrogenics. The remaining authors declare no relevant conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}